Program
Insulin, Regular, Human
Also written as “Technosphere Insulin”, “inhaled human insulin” and “Human Insulin Inhalation Powder”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Asthma · Diabetes, Gestational, led by 13 companies.
Drug pageInsulin, Regular, Human: every studyMany companies study it; this page follows only the 79 they lead. All 127 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mannkindits history only | 261 open or running | phase 4since Apr 16, 2021 | Mar 27, 2006 | Mar 2027phase 2 · NCT07224321 |
| Novo Nordiskits history only | 190 open or running | phase 4since Aug 10, 2006 | Jul 17, 2003 | none ahead |
| Eli Lilly | 100 open or running | phase 4since Jan 22, 2013 | Aug 4, 2005 | none ahead |
| Biodelits history only | 50 open or running | phase 3since Oct 5, 2007 | Oct 5, 2007 | none ahead |
| Pfizerits history only | 40 open or running | phase 3since Feb 2, 2006 | Feb 2, 2006 | none ahead |
| Dance Biopharmits history only | 30 open or running | phase 2since Mar 9, 2016 | Mar 9, 2016 | none ahead |
| Halozyme Therapeuticsits history only | 30 open or running | phase 2since Oct 15, 2008 | Jun 24, 2008 | none ahead |
| Sanofiits history only | 30 open or running | phase 4since Jun 26, 2012 | Sep 2, 2010 | none ahead |
| Transdermal Delivery Solutionsits history only | 21 open or running | phase 3since Dec 1, 2021 | Apr 21, 2021 | Oct 15, 2027phase 3 · NCT05159453 |
| Diabetes and Glandular Disease Clinicits history only | 10 open or running | phase 4since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Informed Data Systemsits history only | 10 open or running | phase 4since Oct 10, 2017 | Oct 10, 2017 | none ahead |
| The United Laboratories Internationalits history only | 10 open or running | phase 1since May 5, 2026 | May 5, 2026 | none ahead |
Also a collaborator on its studies: Langford Research Institute, Insulet, DexCom, Profil Institut für Stoffwechselforschung, Alkermes, WCCT Global and Nektar Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 4, 2005First study: phase 3 study in Diabetes Mellitus, Type 1First studyNCT00127634 · 385 enrolled · United States, Belgium, Canada and more
- Sep 7, 2005Phase 3 study in Diabetes MellitusNCT00157339 · 299 enrolled · United States, Argentina, Bulgaria and more
- May 10, 20062 phase 3 studies in Diabetes Mellitus, Type 2NCT00325364, NCT00330473
- Jul 21, 20062 phase 3 studiesNCT00356109, NCT00355849
- Oct 19, 2006Phase 3 study in Diabetes Mellitus, Type 2NCT00391209 · 379 enrolled · United States, Argentina, Austria and more
- Jun 21, 2007Phase 3 study in Diabetes Mellitus, Type 2NCT00490854 · 129 enrolled · Japan
- Jan 22, 2013Phase 4 study in Diabetes Mellitus, Type 2NCT01774968 · 325 enrolled · United States, Puerto Rico
- Sep 23, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02561078 · 420 enrolled · United States, Puerto Rico
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02561078Diabetes Mellitus, Type 2 · United States, Puerto Rico | 3 | Completed | May 9, 2017 | 420 |
| NCT01774968Diabetes Mellitus, Type 2 · United States, Puerto Rico | 4 | Completed | May 2014 | 325 |
| NCT00490854Diabetes Mellitus, Type 2 · Japan | 3 | Completed | May 2008 | 129 |
| NCT00391209Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | May 2008 | 379 |
| NCT00356109Diabetes Mellitus, Type 1 · United States, Argentina, Belgium and more | 3 | Completed | May 2008 | 494 |
| NCT00355849Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more | 3 | Completed | Jun 2008 | 555 |
| NCT00330473Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Completed | May 2008 | 1,019 |
| NCT00325364Diabetes Mellitus, Type 2 · United States, Brazil, Germany and more | 3 | Completed | May 2008 | 415 |
| NCT00157339Diabetes Mellitus · United States, Argentina, Bulgaria and more | 3 | Completed | May 2008 | 299 |
| NCT00127634Diabetes Mellitus, Type 1 · United States, Belgium, Canada and more | 3 | Completed | May 2008 | 385 |
How it is read
Names in the registry
- “Technosphere Insulin”, 13 entries
- “inhaled human insulin”, 12 entries
- “Human Insulin Inhalation Powder”, 7 entries
- “human insulin”, 7 entries
- “Technosphere® Insulin Inhalation Powder”, 5 entries
Codes read as this program: INH69, INH139, INH208, HR1799.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 33 studies
- Diabetes Mellitus, Type 1, 29 studies
- Diabetes Mellitus, 10 studies
- Asthma, 1 study
- Diabetes, Gestational, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.